THERAVECTYS Taps Alain Clergeot as New CEO
THERAVECTYS Appoints Alain Clergeot Chief Executive Officer
PARIS--(BUSINESS WIRE)--
THERAVECTYS, a French biotech company specialized in lentiviral vector-based therapeutic vaccines and other immunotherapies, is pleased to announce the appointment of Alain Clergeot, MD, as Chief Executive Officer.
Alain Clergeot is physician by training and is graduated from Executive MBA HEC. He practiced Hospital Medicine in France and abroad before joining Schering-Plough Laboratories in 1985.
Two years later he joined Bristol-Myers Squibb as head of clinical research and medical affairs before starting and managing the oncology Business Unit.
He joined Chugai Pharmaceuticals Co. Ltd in 1998 to create the French affiliate, then held Chugai Pharma France’s presidency in 2001 and the responsibility of Head of Operations Europe in 2008.
Alain is Vice-President and co-founder of the Leem Biotech, and member of the board at Paris-Biotech and former member of the Economic, Ethic and Social Board of the Haut Conseil des biotechnologies.
Alain is a seasoned professional in innovation and entrepreneurship and he demonstrated numerous achievements in the pharma and biotech fields over the last twenty five years. As Chief Executive Officer, he will provide his medical, clinical and operational expertise to further develop THERAVECTYS as a leader in immunotherapy against cancers and infectious diseases.
ABOUT THERAVECTYS
THERAVECTYS is a privately-held, fully-integrated discovery & clinical development biotech company, originating from the Institut Pasteur. The company capitalizes on over 15 years of fundamental research in the field of lentiviral vectors and has secured worldwide exclusive rights to Pasteur Institute intellectual property. Based on its lentiviral vector technology platform, THERAVECTYS develops therapeutic vaccines and immunotherapies in oncology and infectious diseases, and has recently achieved a first Phase I/II clinical trial for its vaccine candidate against HIV.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151221005362/en/
Contact:
THERAVECTYS SA
Audrey Bonafos, +33 1 43 90 19 20
abonafos@theravectys.com
or
Milestones – Press Relations
Bruno Arabian, +33 6 87 88 47 26
+33 1 83 62 34 84 barabian@miestones.fr
PARIS--(BUSINESS WIRE)--
THERAVECTYS, a French biotech company specialized in lentiviral vector-based therapeutic vaccines and other immunotherapies, is pleased to announce the appointment of Alain Clergeot, MD, as Chief Executive Officer.
Alain Clergeot is physician by training and is graduated from Executive MBA HEC. He practiced Hospital Medicine in France and abroad before joining Schering-Plough Laboratories in 1985.
Two years later he joined Bristol-Myers Squibb as head of clinical research and medical affairs before starting and managing the oncology Business Unit.
He joined Chugai Pharmaceuticals Co. Ltd in 1998 to create the French affiliate, then held Chugai Pharma France’s presidency in 2001 and the responsibility of Head of Operations Europe in 2008.
Alain is Vice-President and co-founder of the Leem Biotech, and member of the board at Paris-Biotech and former member of the Economic, Ethic and Social Board of the Haut Conseil des biotechnologies.
Alain is a seasoned professional in innovation and entrepreneurship and he demonstrated numerous achievements in the pharma and biotech fields over the last twenty five years. As Chief Executive Officer, he will provide his medical, clinical and operational expertise to further develop THERAVECTYS as a leader in immunotherapy against cancers and infectious diseases.
ABOUT THERAVECTYS
THERAVECTYS is a privately-held, fully-integrated discovery & clinical development biotech company, originating from the Institut Pasteur. The company capitalizes on over 15 years of fundamental research in the field of lentiviral vectors and has secured worldwide exclusive rights to Pasteur Institute intellectual property. Based on its lentiviral vector technology platform, THERAVECTYS develops therapeutic vaccines and immunotherapies in oncology and infectious diseases, and has recently achieved a first Phase I/II clinical trial for its vaccine candidate against HIV.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151221005362/en/
Contact:
THERAVECTYS SA
Audrey Bonafos, +33 1 43 90 19 20
abonafos@theravectys.com
or
Milestones – Press Relations
Bruno Arabian, +33 6 87 88 47 26
+33 1 83 62 34 84 barabian@miestones.fr